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Abstract 
Microglia cells during aging, neurodegeneration and neuroinflammation show different 
morphological and transcriptional profiles (related to axonal direction and cell adhesion). 
Furthermore, expressions of the receptors on the surface and actin formation compared to young 
are also different. This review delves into the role of glia during aging and the development of the 
diseases. The susceptibility of different regions of the brain to disease are linked to the 
overstimulation of signals related to the immune system during aging, as well as the damaging impact 
of these cascades on the functionality of different populations of microglia present in each region of 
the brain. Furthermore, a decrease in microglial phagocytosis has been related to many diseases and 
also has been detected during aging. In this paper we also describe the role of glia in different illness, 
such as AD, ALS, pain related disorders, cancer, developmental disorders and the problems 
produced by opening of the blood brain barrier. Future studies will clarify many points planted by 
this review. 
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Microglia and Aging 
The aged microglia of the human cerebral cortex 
to show different morphological abnormalities, 
including, spherical and knotty shapes, less 
branching, as well as fragmentation processes (1). 
Microglia isolated from post-mortem samples of 
parietal cortex in elderly people also show different 
transcriptional profiles from cells obtained in young 
subjects whose genes are associated with cell 
adhesion, axonal direction, receptor expression on 
their surfaces and actin formation where they were 
especially affected (2). Grabert and his group (3) 
found that changes at the genetic level related to the 
immune system, and to a lesser extent the genes 
related to cellular bioenergy, were widely associated 
with the diversity related to the brain region and its 
age (3). 
Microglia are also greatly affected by aging and 
disease at the molecular level. Using "high- 
dimensional single-cell proteomic mapping" 
techniques, Mrdjen et al., (4), identified diverse 
populations of inflammatory cells, including 
microglia, in the adult mouse brain. In the same way, 
it has also been possible to find remarkable changes 
and the proteomic signature of these cells during 
aging, neurodegeneration and neuroinflammation. 
Compared with cells from young mice, a population 
of aged microglia expresses higher levels of 
phagocytosis associated with the CD11c and CD14 
markers. In addition, different populations of 
microglia were identified in the brains of old mice, 
where the reactive population expressed higher levels 
of CD11c and CD14, CD86, CD44, programming 
ligand of death 1 and MHC-II, and lower levels of 
markers of microglial homeostasis CX3CR1, MerTK 
(C-MER protooncogen tyrosine kinase), and Siglec-H, 








IL-1β, and IL-6 are among the proinflammatory 
cytokines that are overproduced during aging. Cribbs 
and his group (5) suspected that this was caused by 
overstimulation of the transcription factor NF-κB 
when the microglia underwent cell senescence (5). 
Biochemically, aged microglia produce more reactive 
oxidative species and inflammatory cytokines (6). In 
the same way, a positive relationship between these 
oxidative species and inflammatory cytokines has also 
been found in the brain and spinal cord of the 
APP/PS1KI mouse model of Alzheimer's disease (7). 
The overproduction of proinflammatory 
mediators leads to microglia sensitization, or 
age-related microglial priming, so that aged microglia 
produce an exaggerated but inefficient response to 
inflammatory stimuli. Wendeln et al. (8) recently 
demonstrated that peripheral stimulation of mouse 
microglial cells by repeated injection of LPS can cause 
epigenetic changes in these cells for more than six 
months (8). This suggests that the basal level of 
inflammation in microglia can be increased with 
repetitive inflammatory stimuli, potentially being the 
cause of microglial priming. Cumulative and lasting 
changes in the balance of inflammatory mediators 
worsen the ability of microglia to perform basic 
physiological functions and are probably a 
contributing factor in neurodegenerative processes. 
For example, young microglia can more efficiently 
phagocytose disease-related proteins, such as Aβ (9) 
and α-synuclein (10) than aged microglia. Similarly, it 
has been shown that aged microglia decrease motility, 
vigilance, and phagocytic responses to demyelinating 
lesions (11), in part due to reduced lysosomal function 
(12). Taken together, these studies suggest that the 
susceptibility of different regions of the brain to 
Alzheimer's disease (AD) may be linked to the 
overstimulation of signals related to the immune 
system during aging, as well as the damaging impact 
of these cascades on the functionality of different 
populations of microglia present in each region of the 
brain. 
Decrease in Microglial Phagocytosis 
during Aging 
As the main phagocytic cells in the brain, 
microglia play a central role in the clearance of Aβ. 
However, the effectiveness of this clearance decreases 
during aging, and particularly in AD (9). Despite its 
inability to clear Aβ from the brain, microglia 
continue to release proinflammatory mediators to 
further stimulate the immune response, thus creating 
a cycle that leads to the accumulation of activated 
immune cells, inflammatory mediators and Aβ. This 
cycle which is partially caused by microglia 
senescence has been reported by Thakker et al. (13) 
and can be reversed by blocking Aβ synthesis. (13). 
The microglia of old APP / PS1 mice exhibit lower 
expression of the scavenger receptor A (for its 
acronym in English SRA), CD36 and the receptor for 
RAGE (three scavenger receptors for beta-amyloid 
binding) when compared to that observed in the cells 
from young mice. By contrast, microglia from the 
group of APP / PS1 mice expresses higher levels of 
the proinflammatory cytokines, IL-1β and TNF-α, 
suggesting that there is an inverse correlation 
between the production of pro-inflammatory 
cytokines and clearance of Aβ. This idea is supported 
by in vitro studies in which treatment of microglia 
with TNF-α resulted in a reduction of the expression 
of SRA and CD36, and uptake of Aβ (14). In AD 
mouse models, microglia also show substantial 
deterioration in calcium signalling (15) and beclin-1 
mediated recycling of phagocytic receptors CD36 and 
Trem2 (16), which are linked to a poor internalization 
of Aβ.  
Based on longitudinal studies of images of the 
human brain, Fan et al. indicated the state of microglia 
activation changes from an early protective 
phenotype to a late and noxious phenotype during the 
progression of AD (17). The chronic activation of 
different populations of microglia could be associated 
with the change in the global microglial phenotype 
depending on whether they are CX3CR1 + for the 
production of inflammatory mediators or Trem2 + for 
phagocytosis of Aβ (18). 
Although there is strong evidence that aging 
impairs microglial activity, the relationship between 
microglial senescence, Aβ and AD remains 
incomplete, given that some studies have shown that 
microglial phagocytic activity towards Aβ is not 
necessarily related to changes in neurotoxicity and 
cognition. Investigations using the APP J20 mouse 
model have revealed that the inhibition of microglial 
phagocytic activity by minocycline before the 
accumulation of Aβ results in an increase in amyloid 
plaque burden, reduced inflammation, and improves 
cognitive performance, which indicates that chronic 
inflammation can interrupt normal neuronal function 
independent of Aβ. However, when microglial 
inhibition is performed after Aβ deposition begins, 
inflammation is suppressed by minocycline with no 
effect on amyloid plaque loading or in the 
improvement in cognitive performance (19). To add 
even more controversy to the relationship between 
inflammation and AD, the pharmacological or genetic 
suppression of microglia after Aβ accumulation does 
not change the plaque levels but prevents dendritic 
loss of the vertebral spine, neuronal loss and improves 
cognitive performance (20,21). 




Alzheimer’s Disease and Glia 
In Alzheimer's disease, complex changes and 
specific conflicts occur in different brain regions. The 
number of reactive astrocytes increases, engulfing and 
reducing the amyloid plaques. In addition, astrocytes 
surround the amyloid plaques and secrete 
proinflammatory factors in the extracellular space 
(22). Currently, no single hypothesis about what 
causes AD has been proven, a fact which argues for 
the heterogeneity of this dementia. For decades, it has 
been thought by many that the amyloid cascade 
hypothesis was the correct cause and this thinking 
was supported and promoted financially by a host of 
pharmaceutical companies around the world. The Aβ 
hypothesis argues that in AD there is an increase in 
oxidative stress caused by the accumulation of Aβ and 
that its elimination has been a priority but without 
positive results to the patients. There are much 
researches showing that increased levels of ROS have 
been linked to AD (23) but the effects of antioxidants 
in clinical studies have been disappointing, either 
because high concentrations of antioxidants are 
pro-oxidants, or because oxidative stress occurs 
relatively early in the course of the disease, or, 
because the combination of antioxidants fails in the 
clinical stage. Analogous to microglia, astrocytes play 
multiple roles in the organization and maintenance of 
brain structure and function. Multiple studies show 
that astrocytes dynamically modulate information 
processing, signal transmission, neural and synaptic 
plasticity, as well as homeostasis control of the 
blood-brain barrier. The astrocytic role in immune 
responses is not entirely clear. The evidence suggests 
that, astrocytes act as a protector during cerebral 
ischemia, whereas against inflammation mediated by 
the lipopolysaccharide of Escherichia coli, its 
intervention seems to be harmful (24). In the cells of 
the retina, however, it has been reported that through 
the production of lipoxins, astrocytes have an 
anti-inflammatory and neuroprotective effect against 
acute and chronic lesions (25). Similarly, the role of 
the cytokine IL-33 produced by astrocytes has recently 
been demonstrated to the microglial approach to the 
synaptic terminals, as well as the development of 
neural circuits (26). From prior studies discussed 
above on the action of IL-1α +, it may be concluded 
that there is also a correlation between IL-1α and the 
greater number of GFAP + astrocytes 
(GFAP-immunoreactive astrocytes) (27). Conversely, 
it has been demonstrated in a study carried out in 
mice with multiple sclerosis that signals of the 
proinflammatory cytokine TNF-α promote in 
astrocytes a change in synaptic transmission and 
produce interference at the cognitive level (28). Other 
studies have shown that the activation of certain 
transcription factors are also involved in protective 
(STAT3) (29) or injurious (NF-κB) effects (30). More 
details about the relationships between glia cells and 
Alzheimer's disease can find them in (31).  
Amyotrophic Lateral Sclerosis (Als) and 
Glia 
In ALS cortical and spinal motor neurons suffer 
damage, sequentially or simultaneously. Until 25 
years ago, astrocytes were only considered the 
architecture of the CNS. Since then, many other 
functions have been described for these cells. The 
astrocytes adapt their function to the needs of neurons 
associated with them, and vary according to the 
mission they need to perform (32,33). The population 
of astrocytes connected to a neuron group have 
defined functions and morphological characteristics 
that are different from other astrocytic populations. 
Fibrous astrocytes have a fusiform body located in 
parallel with nerve fibers and produce extensions 
even directly on the nodes of Ranvier. (32,34). Each 
astrocyte controls a space with several motor neurons 
and makes contact with 3 to 10 neurons, hundreds of 
dendrites and with multiple synapses (35). Astrocytes 
connect to each other through gap-junctions (GJs). 
The GJs do the intercellular communication through 
ion exchange (electrical coupling) and the passage of 
small molecules (metabolic coupling) develops a type 
of syncytium that extends across the CNS. Therefore, 
all astrocytes in the brain constitute a network that 
helps neurons and other types of brain cells in the 
brain, controlling inflammation, oxidative stress, and 
brain nutrition (36). Furthermore, astrocytes control 
microglia and the inflammatory reaction produced by 
macrophages. The GJs communicate with 
protoplasmic and fibrous astrocytes, with neurons 
and their extensions as well as with arterioles (37). 
Motor neuron death, which occurs through 
mitochondrial, cytoplasmic apoptosis or 
vacuolization (38,39), can affect neurons by noxious 
circumstances. Astrocytes are also important because 
any alteration that affects cortical or spinal neurons 
will cause consequences in neurons far removed. 
However, astrocytes have different populations 
surrounding neuron types and that is true for 
protoplasmic astrocytes, which make contact with 
neurons, and for fibrous astrocytes that contact 
neuronal extensions (40,41). A recent paper, published 
by Larrodé et al. (42), demonstrated the involvement 
of DREAM (Downstream Regulatory Element 
Antagonist Modulator) in ALS. This protein could be 
used as a novel therapeutic target to treat ALS, but 
further studies are needed to understand the 
molecular mechanism of DREAM in ALS.  
ALS begins within a group of cortical and/or 




spinal neurons, and protoplasmic astrocytes may send 
toxic mediators to other protoplasmic cells 
surrounding different neuronal groups. Furthermore, 
protoplasmic astrocytes are normally in 
communication with fibrous astrocytes connecting 
that with axons of the pyramidal cells (43). It is 
possible that these protoplasmic astrocytes could 
induce lethal damage in the cells implicated.  
Glia and Its Role in Pain 
Pain plays a protective body role that functions 
as a signal of damage. Pain can convert into a disease 
when it persists more than 3 or 4 months (chronic 
pain) (44). In the sensory ganglia, particularly in the 
dorsal spinal ganglia, there are different types of cells. 
Cultures of the dorsal spinal ganglia in the rat 
demonstrate a presence of organized cells, seen using 
light and electron microscopy. These cells surround 
each body and the proximal portion of a neuronal 
axon forming a sheath around the cell. Each unit is a 
morphological and functional distinct body (45) and 
every unit is locked on with a neighbor by adhesion 
and gap junctions. Satellite glial (SG) cells are 
important in non-physiological pain and are a 
potential target for the development of new pain 
treatments (46). The cells in the sensory ganglia are 
surrounded by neuronal bodies presenting different 
functional units with bidirectional communication 
signaling between both types of neural cells. SG cells 
develop biochemical and structural changes after 
nerve damage, and consequently, the development of 
pain in animal models (47,48). A somatic release of 
chemical mediators, dependent on Ca2+, occurs after 
electric or chemical stimulation which alter somatic 
excitability in the sensory ganglia (49), such as 
substance P, glutamate, adenosine triphosphate, 
γ-amino-butyric acid and CGRP (calcitonin gene 
related peptide) (50,51).  
The communication between cells in the sensory 
ganglia (SG), neuron-neuron; neuron-SG or SG-SG, 
can affect the communication between cells. The SG 
cells can modulate chronic pain (52,53) and sensory 
ganglia can be the pathophysiological first level of 
chronic pain. Furthermore, interaction between SG 
cells and neurons is becoming more and more 
important in the therapeutic field of chronic pain.  
Glia and Cancer 
Tumor types are determined by age, size and 
location. In infancy and adolescence, infratentorial 
astrocytoma and midline tumors such as 
medulloblastoma and pinealoma predominate. In 
adulthood, anaplastic astrocytoma and glioblastoma 
are more common (54). Glioblastoma is the most 
common tumor detected in the brain, although the 
most frequent tumor seen at autopsy is meningioma. 
Secondary glioblastomas progress from low-grade 
diffuse astrocytoma or anaplastic astrocytoma (55). 
Some brain tumors, schwannoma, sarcoma, glioma 
and meningioma, persist after the patient has been 
exposed to chemotherapy and/or radiation therapy. 
In Epstein Barr virus and in primary brain lymphoma, 
virus infections are involved and in many cases, they 
are associated with AIDS. 
Astrocytes are strongly associated with cancer in 
the brain (56) as cancerous astrocytoma. There are 
three different astrocytoma types, pilocytic, diffuse 
and anaplastic astrocytoma. Pilocytic astrocytoma is 
always treated by surgery and is more prevalent in 
children (57). In diffuse astrocytoma, surgery and 
radiotherapy is generally recommended. In anaplastic 
astrocytoma the same treatment as that for 
glioblastoma is used (indicated below) (58). 
Investigation of astrocytomas has been studied with 
the use of anti-cancer stem cell drugs (59). Another 
type of cancer is glioblastoma multiform which 
represents 20 % of all intracranial tumors, constituting 
half of all glioblastomas. They grow from tissue 
surrounding nerve cells and normally start in the 
cerebral hemispheric part of the brain. It affects 60% of 
men and 40% of women. They have high malignancy, 
producing quick invasion of the brain tissue (60). 
Because of their malignancy, natural and synthetic 
drugs have been used (61). Targeting cholesterol 
metabolism has also been used in cancer therapy to 
control changes in aberrant cholesterol production in 
neuroblastoma (62). 
Non-neuron cells can develop cancer, such as 
astrocytes, and oligodendroglia. The neurons are 
differentiated cells, so they cannot produce cancer. 
The neuroblastoma cells are radial glia or precursors 
of astrocytes that can develop before their 
differentiation to neurons. Glial cells develop 
different types of cells such as neurons, 
oligodendroglia and astrocytes (63). All these types of 
cells can convert to cancer and affect the normal 
function of the brain). Radial glia are stem cells that 
develop from a progenitor stem cell in the embryo 
and in the adult brain (64). It is of interest to point out 
that in some astrocytomas, the patient may increase 
cognitive capacity and memory, before the illness 
starts and even when cancer is already present (65).  
Glia and Developmental Disorders 
Astrocytes play a role in the aberrant formation 
of neuronal circuitry in the brain. This field in 
neuroscience is relatively new and shows us the 
involvement of astrocytes in psychiatric disorders, 
including autism spectrum disorders (ASDs), bipolar 
disorders (BD) and schizophrenia (66,67). The 




expression of the MicroRNAs are critical in the 
development of prefrontal cortical circuitry during 
the postnatal brain development. Deficits in neuronal 
maturation produced by the microRNAs decrease 
and/or become deficient and can be demonstrated in 
some neuropsychiatric diseases (67). Coordination of 
the different neural cell types is fundamental in the 
development of the neural network and in normal 
neural function. Astrocytes coordinate neural 
development by controlling the formation of 
synapses, neuronal function, driving axon growth, 
and promoting neuronal survival (68). Astrogenesis 
occurs after neurons develop in the brain of rats (64), 
and in other animals, including humans (69). During 
development of the brain, chromatin changes occur 
and defects in astrogenesis or in early function of 
astrocytes that can produce the progression of 
neurodevelopmental disorders (68). 
The Opening of the Blood-Brain Barrier 
during Aging 
Another characteristic of aging with relevance 
for AD is the increase in the permeability of the 
blood-brain barrier (BBB) to immune cells and the 
peripheral tissue molecules. The loss of integrity of 
the BBB appears to occur prior to hippocampal 
atrophy (70,71) and cognitive impairment (72), 
suggesting that this decomposition precedes the 
neurodegenerative process in AD. This evidence also 
indicates that the peripheral activation of the immune 
system may contribute to the deterioration of brain 
function and the neurodegenerative processes that 
occur in AD (73). Interestingly, an association has 
recently been made between inflammation in 
middle-aged individuals and brain volume in older 
individuals. Compared with middle-aged people 
without elevated inflammatory markers, individuals 
with elevations in 3 or more markers had, on average, 
5% more decreased of the volume hippocampus, 
typical of the AD. (71). In healthy individuals, those 
responsible for the proper functioning of 
neurovascular function are the pericytes, endothelial 
cells and astrocytes, which form fine junctions 
between endothelial cells in response to inflammation 
that limit the consequent mobilization of immune 
cells from the periphery. It has been found that 
inhibiting the formation of the inducible astrocytic 
barrier increases the severity of the disease in mouse 
models. In this way, it is suspected that the senescence 
of the cellular components that form this barrier is one 
of the causes behind the malfunction of the BBB (74).  
Endothelial cells, pericytes and astrocytes in the 
BBB are particularly vulnerable to the effects of aging 
and chronic stimulation by inflammatory mediators. 
During aging, endothelial cells in the mouse brain 
express higher levels of TNF-α and decreased 
expression of the narrow-binding proteins ocludin-1 
and zonula occludens1, which correlate with an 
increase in peripheral inflammation (75). Aging and, 
more aggressively, AD, also cause damage to the 
pericytes as evidenced by the increase in 
β-platelet-derived growth factor receptor levels 
observed in experiments performed on mice (70). 
Although the mechanism of induction of pericyte 
lesions is still unknown, Bell and his collaborators 
have shown that age-dependent vascular damage in 
pericyte-deficient mice precedes neuronal 
degenerative changes, learning and memory 
impairment, and neuroinflammatory response (76). 
In astrocytes, transcriptome analysis has 
revealed that aging induces upregulation of several 
genes related to the immune system (77). An 
age-dependent change in the phenotype of the 
astrocytes was identified by comparing gene 
expression in the astrocytes of 10-week and 2-year-old 
mice using RNAseq. It has been demonstrated that 
IL-1β suppresses the astrocytic expression of "sonic 
hedgehog" (78), a protein that protects the BBB by 
upregulation of the tight binding proteins in capillary 
endothelial cells (79). Similarly, this study 
demonstrated that astrocytes from healthy 2-year-old 
mice expressed genetic markers that correspond to the 
activated A1 phenotype, including C4a, C3, 
Serpina3n, and Cxcl10 (80). IL-1β also increases the 
production of proinflammatory chemokines such as 
CCL2, CCL20 and CXCL2 by astrocytes, which 
induces the migration of immune cells from the 
periphery and exacerbates BHE malfunction and 
neuroinflammation (78). Therefore, an excessive 
proinflammatory phenotype significantly alters the 
protective role of astrocytes in the maintenance of BBB 
integrity. 
Inflammation and aging are therefore closely 
linked thanks to studies suggesting that low levels of 
inflammation correlate better with healthy brain 
function (71) and longevity (81). Considering that 
most cells in the brain, including astrocytes (30) and 
microglia (82), have a long lifespan, it is plausible that 
the accumulation and overstimulation of 
Inflammation can trigger multiple cumulative 
molecular modifications (telomere shortening, DNA 
damage, epigenetic modifications, lysosomal 
dysregulation) that eventually contribute to cellular 
senescence and loss of function. This idea is, at least in 
part, supported by a repopulation study in a 
neurodegeneration model of mice, which showed 
that, following a pharmacologically induced cell 
depletion, the microglia that repopulated the brain 
showed the morphological phenotype of young cells. 
Surprisingly, the animals also showed a significant 




improvement in brain function (83). It is still 
unknown that cell repopulation methods can restore 
the molecular signatures of immunesenescence. 
Additional studies are needed to clarify the 
underlying cellular and molecular mechanisms 
related to the immune dysregulation that occurs 
during aging that divert individuals from the 
relatively benign process of normal brain aging to the 
pathological processes associated with AD. 
Conclusion 
The functions that the glia develops, both during 
the age and the illness, is an important field of study 
at present. The most important brain cells can be 
divided into neurons and glia. For many years 
research has focused on neurons, but increasingly the 
glia has becoming more important. Within the glia are 
the astrocytes, oligodendroglia and microglia. Many 
diseases affect one or several of these cells. From 
Alzheimer's disease, amyotrophic lateral sclerosis, 
pain-related diseases, cancer and developmental 
disorders, we know now that glia play an important 
role in the development of their diseases. Studies are 
needed to clarify the underlying cellular and 
molecular mechanisms related to the immune 
dysregulation that occurs during aging that divert 
individuals from the relatively benign process of 
normal brain aging to the pathological processes 
associated with different diseases. 
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